The announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager (PBM) Catamaran for $12.8 billion officially puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Michael Griffith.
Albert Wertheimer, PhD, MBA, Professor of Pharmaceutical Economics at Temple University and a member of Pharm Exec's Editorial Advisory Board, shows how the simple matter of a drug shortage is not a simple matter at all.
The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric — combined. It's counterintuitive…if not overwhelming, writes Lisa Barbadora